



2. The compound of claim 1, wherein the compound has the structure:




or a pharmaceutically acceptable salt thereof.

3. The compound of claim 2, wherein the compound has the structure:




or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1, wherein the compound has the structure:



or a pharmaceutically acceptable salt thereof.

5. A compound having the structure:



or a pharmaceutically acceptable salt thereof.

6-8. (canceled)

9. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

10-19. (canceled)

20. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of claim 1.

21-24. (canceled)

25. The method of claim 20, wherein the cancer is non-small cell lung cancer, colorectal cancer, bladder cancer, cancer of unknown primary, glioma, breast cancer, melanoma, non-melanoma skin cancer, endometrial cancer, esophagogastric cancer, esophageal cancer, pancreatic cancer, hepatobiliary cancer, soft tissue sarcoma, ovarian cancer, head and neck cancer, renal cell carcinoma, bone cancer, non-Hodgkin lymphoma, small-cell lung cancer, prostate cancer, embryonal tumor, germ cell tumor, cervical cancer, thyroid cancer, salivary gland cancer, gastrointestinal neuroendocrine tumor, uterine sarcoma, gastrointestinal stromal tumor, CNS cancer, thymic tumor, adrenocortical carcinoma, appendiceal cancer, small bowel cancer, penile cancer, bone cancer, or hematologic cancer.

26-29. (canceled)

30. The method of claim 25, wherein the cancer is melanoma.

31. (canceled)

32. The method of claim 30, wherein the melanoma is uveal melanoma.

33. (canceled)

34. The method of claim 20, wherein the cancer is hematologic cancer.

35. The method of claim 34, wherein the hematologic cancer is acute myeloid leukemia.

36-41. (canceled)

42. The method of claim 20, wherein the cancer expresses BRG1 and/or BRM protein.

43-46. (canceled)

47. The method of claim 20, wherein the cancer has, or has been determined to have, a KRAS mutation, a mutation in GNAQ, a mutation in GNA11, a mutation in PLCB4, a mutation in CYSLTR2, a mutation in BAP1, a mutation in SF3B1, a mutation in EIF1AX, a TFE3 translocation, a TFEB translocation, a MITF translocation, an EZH2 mutation, a SUZ12 mutation, and/or an EED mutation.

48. The method of claim 20, wherein the cancer is metastatic.

49. The method of claim 20, wherein the cancer is resistant to, or failed to respond to prior treatment with, an anticancer therapy.

50-53. (canceled)

54. The method of claim 20, wherein the method further comprises administering to the subject an anticancer therapy.

55-58. (canceled)

59. A method for treating a viral infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of claim 1.

60-64. (canceled)

\* \* \* \* \*